Biotechnology is a broad discipline in which biological processes, organisms, cells or cellular components are exploited to develop new technologies. New tools and products developed by ...
Vir Biotechnology (VIR) has signed a collaboration and license agreement with Gilead focused on three PRO-XTEN dual-masked ...
In this column, the author discusses how food biotechnology is evolving from scientific innovation into a scalable ...
Vir Biotechnology is approaching multiple clinical readouts from drugs with positive data previously. Click here to read an ...
Nautilus Biotechnology, Inc. reported its financial results for the third quarter ended September 30, 2026. Revenue was $0.2 million for the third quarter of 2026, primarily driven by grant revenue ...
The Treasury Department’s proposed restrictions on U.S. investment in Chinese biopharma collide with Beijing’s new export ...
WASHINGTON, November 29, 2022 (Newswire.com) - The Smithsonian Science Education Center, in collaboration with the InterAcademy Partnership (IAP), has developed Biotechnology! How can we ethically ...
Biotechnology is a curious marriage of two seemingly disparate worlds. On one end, we have living organisms—wild, unpredictable celestial creations that can probably never be understood or appreciated ...
Kos Biotechnology Partners ("Kos"), a global life sciences investment firm bridging the U.S. and European biopharma ...
The Treasury Department is proposing rules to add biotechnology to its Outbound Investment Security Program under the COINS Act. The U.S. Department of the Treasury issued a Notice of Proposed ...
Nautilus Biotechnology (NAUT) is scheduled to announce Q3 earnings results on Tuesday, October 27th, before market open. The consensus EPS Estimate is -$0.14 and the consensus Revenue Estimate is ...
Stem cell biotechnology is a field of biotechnology that develops tools and therapeutics through modification and engineering of stem cells. Stem cell biotechnology is important in regenerative ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results